Pharma: Page 56
-
Anthem joins insurer-backed generics effort CivicaScript
The subsidiary of hospital-owned nonprofit CivicaRx plans to make six to 10 common generic drugs that don't have enough competition to drive down cost.
By Rebecca Pifer Parduhn • June 16, 2021 -
Chip Somodevilla via Getty Images
Former FDA chief Hahn joins venture firm that launched Moderna
Hahn's appointment as chief medical officer of Flagship Pioneering is another example of FDA officials joining industry after their government service. Hahn's predecessor, Scott Gottlieb, sits on Pfizer's board of directors.
By Jonathan Gardner • June 15, 2021 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Permission granted by Emergent Biosolutions
Sponsored by Emergent BiosolutionsLyophilized products are on the rise: Here's what you need to know
To extend the shelf life and improve stability of biopharmaceuticals, a freeze-drying process—and a partner—can help.
By Kate Silver • June 14, 2021 -
Sarah Silbiger via Getty Images
As trials progress, FDA weighs COVID-19 vaccine authorizations for children
An advisory panel could not reach consensus on how long or large trials in young children should be. Some experts argued falling infection rates might mean vaccination of kids under 12 is unnecessary.
By Jonathan Gardner • June 11, 2021 -
Permission granted by Bristol-Myers Squibb
Bristol Myers says CAR-T therapy beat chemo, transplant in lymphoma study
The results could help support taking CAR-T therapy into earlier lines of cancer treatment, a long-held goal for the complex cellular drugs.
By Ned Pagliarulo • June 10, 2021 -
Brian Tucker/BioPharma Dive
Deep Dive'The lights are no longer green': Antitrust regulators reassess pharma deals
The FTC and its counterparts abroad are rethinking their approach to drugmaker acquisitions. Past scrutiny offers clues to where they may look next.
By Jonathan Gardner • June 10, 2021 -
Erik S. Lesser via Getty Images
US bets $1.2B on Merck's last hope for a COVID-19 drug
Though most of Merck's COVID-19 efforts have come up short, its antiviral pill could still have a role, as signaled by the U.S. government's sizable financial commitment.
By Ben Fidler • June 9, 2021 -
Biogen Alzheimer's approval could open the door for similar drugs
Approval of Aduhelm sets a precedent that could enable some drugs, like Eli Lilly's drug donanemab, to advance quickly and cause other previously sidelined ones to get a second look.
By Jonathan Gardner • June 9, 2021 -
Novo keeps price in line with FDA approval of second obesity shot
Wegovy, a weekly drug, joins daily Saxenda in the pharma's portfolio, which could soon be under pressure from an experimental Lilly medicine.
By Jonathan Gardner • June 7, 2021 -
Lisa Maree Williams via Getty Images
Alexion, AstraZeneca executives switch roles amid $39B buyout
Marc Dunoyer, the U.K. drugmaker's longtime finance chief, will move over to a strategy role and run Alexion as a rare disease unit within AstraZeneca.
By Jonathan Gardner • June 4, 2021 -
Permission granted by Bristol-Myers Squibb
Bristol Myers sued over delayed approval of cancer cell therapy
A bank representing former Celgene shareholders claims Bristol Myers did not work diligently to secure FDA clearance of Breyanzi, one of three drugs covered by a $6.4 billion agreement between the two companies.
By Ned Pagliarulo • June 4, 2021 -
Ewa Krawczyk, National Cancer Institute
An AstraZeneca, Merck drug slows the return of genetic breast cancer. Will testing speed up?
New study results could make Lynparza a standard adjuvant treatment for people with an inherited form of breast cancer — as long as they know they have it.
By Ben Fidler • June 3, 2021 -
Novartis prostate cancer drug extends survival in key test of radiopharmaceutical therapy
Results from the Phase 3 trial, which Novartis plans to use to ask for approval, help validate the pharma's bet on the therapy's original developer, Endocyte.
By Ned Pagliarulo • June 3, 2021 -
David Paul Morris via Getty Images
Former FDA official Abernethy joins Google health spinoff
The agency's former acting CIO pushed development of real world evidence as well as improved data sharing. At Verily, she'll head up the unit's clinical research business.
By Jonathan Gardner • June 3, 2021 -
ICER, vocal critic of drug company pricing, turns scrutiny to insurers
The watchdog group plans to examine how cost sharing can hurt access to care, but it won't assess some of the most controversial insurer practices.
By Jonathan Gardner • May 25, 2021 -
Sarah Silbiger via Getty Images
J&J's new cancer drug leads a growing pipeline of dual-targeting antibodies
Pharma and biotech companies alike see potential in using bispecific antibodies for hard-to-treat cancers like leukemia, myeloma and solid tumors.
By Jonathan Gardner • May 24, 2021 -
Courtesy of Eli Lilly
Coronavirus variants threaten to undermine another Lilly COVID-19 drug
One month after Lilly's first coronavirus antibody was pulled from market, the U.S. government stopped distributing its other treatment in two states.
By Ben Fidler • May 24, 2021 -
Sean Gallup via Getty Images
Pfizer, BioNTech to send EU up to 1.8B coronavirus vaccine doses
The deal, which the companies and the bloc have been negotiating for weeks, will significantly expand on the current contract for 600 million shots.
By Kristin Jensen • May 20, 2021 -
Off-the-shelf CAR-T, a Tagrisso rival and the next breast cancer drugs
Study abstracts for drugs from Allogene, EQRx, Sanofi and Lilly drew early interest and helped set the stage for the meeting.
By Ben Fidler , Ned Pagliarulo • May 20, 2021 -
Permission granted by Bristol-Myers Squibb
Closely watched Bristol Myers immunotherapy shows benefit in melanoma
Study results prove, for the first time, that a drug blocking the protein LAG-3 can improve on another immunotherapy.
By Ned Pagliarulo • May 19, 2021 -
Win McNamee via Getty Images
Humira patents take center stage as House panel targets AbbVie pricing
CEO Richard Gonzalez defended the company's practices, arguing its profits help spur innovation: "The products that are on the market today pay for the products of the future," he said.
By Jonathan Gardner • May 18, 2021 -
Permission granted by Bristol-Myers Squibb
Bristol Myers pays Agenus $200M for drug aimed at top immunotherapy target
The pharma acquired rights to an experimental antibody medicine that blocks a protein, called TIGIT, that's become a focus for several cancer drugmakers.
By Ned Pagliarulo • May 18, 2021 -
Novartis challenge to Amgen's Enbrel patents ends at Supreme Court's door
The top court declined to hear Novartis' appeal of an earlier federal ruling in Amgen's favor, likely preventing biosimilar competition until 2029.
By Ned Pagliarulo • May 18, 2021 -
Kena Betancur via Getty Images
Deep DiveTrump tax law cut what US drugmakers owed. Now they fear an increase.
The 2017 law saved pharmaceutical companies billions of dollars, BioPharma Dive found. Executives are now fiercely opposing tax hikes proposed by President Biden, claiming they've since boosted domestic investment.
By Jonathan Gardner • May 17, 2021 -
Courtesy of Sanofi
Sanofi, GSK say revamped coronavirus vaccine is strong enough for final test
The two drugmakers, set back last December after an earlier version underperformed, reported positive results from a Phase 2 study.
By Ned Pagliarulo • Updated May 17, 2021
Previous
